Tribune Therapeutics Raises €37M to Develop Anti-Fibrotic Therapies
Posted on April 3rd, 2025
Tribune Therapeutics, co-founded by SPARK Norway alumnus Ole Joergen Kaasbøll, has raised €37 million in Seed and Series A funding to accelerate its anti-fibrotic drug development. The company is focused on creating novel therapies for fibrotic diseases, which remain a major unmet medical need. This milestone highlights the growing impact of SPARK alumni in advancing innovative biotech solutions.
Permalink: https://sparkglobal.io/tribune-therapeutics-raises-e37m-to-develop-anti-fibrotic-therapies/